MedTrace Logo

Follow-up in Rivaroxaban Patients in Setting of Thromboembolism

NCT02248610 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1343

Last updated 2020-08-12

No results posted yet for this study

Summary

In patients with acute clots (deep vein thrombosis or pulmonary embolism) the investigators will collect real world data on their short and long term outcomes. The investigators hypothesise that in patients treated from the outset with rivaroxaban that: 1. treatment will be non-inferior to treatment with conventional anticoagulants (heparins and warfarin); 2. there will be less bleeding than when patients are on conventional anticoagulants; 3. there will be a lower long-term incidence of morbidity from chronic thromboembolic pulmonary hypertension and post-thrombotic limb syndrome.

Conditions

  • Venous Thromboembolism

Interventions

OTHER

Non-interventional study

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • King's College Hospital NHS Trust

    lead OTHER

Principal Investigators

  • Roopen Arya, MBChB, PhD · King's College Hospital NHS Trust

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-11-30
Primary Completion
2020-07-31
Completion
2020-07-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02248610 on ClinicalTrials.gov